Literature DB >> 2491632

Double stranded DNA binding in autoimmune chronic active hepatitis and primary sclerosing cholangitis starting in childhood.

M Peakman1, L Bevis, G Mieli-Vergani, A P Mowat, D Vergani.   

Abstract

Autoimmune chronic active hepatitis (aCAH) and primary sclerosing cholangitis (PSC) are liver disorders occurring in childhood in which non-organ specific autoantibodies, such as anti-nuclear antibody (ANA) are frequently found. Antibodies to double stranded DNA (dsDNA), which are typically present in systemic lupus erythematosus (SLE), have been detected in both acute and chronic liver diseases in adults. In this study, using a radioimmunoassay technique widely employed to measure antibodies to dsDNA, we have demonstrated significantly increased levels (median and range; 11.9, 1.0-36.5 U/ml) in 21 children with aCAH compared with normal children (1.0, 0.7-2.1 U/ml; p less than 0.01). Five children with aCAH had levels in the range considered diagnostic for SLE (greater than 25 U/ml) and of these, three had ANA and two had anti-liver kidney microsomal antibody. In addition, one child had antibodies to dsDNA as detected by the Crithidia luciliae test. DNA binding in aCAH was correlated with serum aspartate-amino transferase levels (r = 0.68; p less than 0.001), suggesting a direct relationship with disease activity. In PSC, levels of antibodies to dsDNA were significantly increased compared to normal controls (median and range; 7.0, 5.6-10.2 U/ml; p less than 0.01) but were not as high as those found in aCAH.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2491632     DOI: 10.3109/08916938908997097

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  1 in total

1.  Antinuclear antibodies (ANA) as a criterion for classification and diagnosis of systemic autoimmune diseases.

Authors:  Luis Eduardo C Andrade; Jan Damoiseaux; Diego Vergani; Marvin J Fritzler
Journal:  J Transl Autoimmun       Date:  2022-01-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.